Encorium Group, Inc. Announces $3.2 Million of New Business Contracts for Europe and North America

WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical and biotechnology companies, today announced $3.2 million of additional new business contracts for Europe and North America. The therapeutic areas included in these awards are oncology, asthma, diabetes, rheumatology, and immunology/vaccines. Services to be provided include consulting, regulatory affairs, project management, field monitoring, and medical monitoring/writing. Revenue recognition for many of these contracts will begin in the current second quarter of 2008 with the remainder expected to occur on a proportional performance basis as services are performed on each project.